Innate Pharma

Report Publication Announcement • Jan 5, 2016

UPCOMING INVESTOR CONFERENCES

Marseille, France, January 5, 2016

Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at the following investor events during the first quarter of 2016:

• Oddo Midcap Forum Lyon, January 7-8, 2016
• J.P. Morgan 34th Annual Healthcare Conference San Francisco, CA, January 11- 14, 2016
• Invest Securities Biomed event Paris, January 27, 2016
• Leerink Global Healthcare Conference New York, NY, February 10-11, 2016
• Credit Suisse Healthcare Conference London, March 1-2, 2016
• Oddo Biotech / Medtech Forum Paris, March 31, 2016

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (www.innatepharma.com/en/financials).

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb and Novo Nordisk A/S.

The Company has three clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma's science also has potential in chronic inflammatory diseases.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 112 employees as at September 30, 2015.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code Ticker code FR0010331421 IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press

Laure-Hélène Mercier Director, Investor Relations

Tel.: +33 (0)4 30 30 30 87 investors@innate-pharma.com presse@atcg-partners.com

Marie Puvieux (France) Mob: +33 (0)6 10 54 36 72